Aline Lopes Chagas

Aline Lopes Chagas

Auto-generated profile, based on publicly available information

Aline Lopes Chagas

Division of Hepatology, Department of Gastroenterology, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Open access
ACAline L. Chagas
Aline L. Chagas
GFGuilherme E.G. Felga
Guilherme E.G. Felga
MDMarcio A. Diniz
Marcio A. Diniz
RSRenato F. Silva
Renato F. Silva
AMAngelo A. Mattos
Angelo A. Mattos
FCFlair J. Carrilho
Flair J. Carrilho
Background: Liver transplantation (LT) is the treatment of choice for patients with unresectable early hepatocellular carcinoma (HCC). Post-LT HCC recurrence rates range from 8 to 20% and still impact on overall survival (OS). The aim of our study was to evaluate the impact of HCC recurrence on post-LT survival and analyze prognostic factors among those patients with recurrence. Patients and methods: We carried out a national, multicenter, retrospective cohort study in Brazil. Medical records of 1119 LT recipients with HCC were collected. Data from patients with post-LT HCC recurrence were analyzed and correlated with post-relapse survival. Results: OS of the 1119 patients included in the study was 63% over 5 years. Post-LT HCC recurrence occurred in 86 (8%) patients. The mean time to recurrence was 12 months. Sites of recurrence were extrahepatic in 55%, hepatic in 27%, and both hepatic and extrahepatic in 18%. Recurrence treatment was performed in 50 (64%) cases, mostly with sorafenib. Post-relapse survival rates were 34% at 1 year and 13% at 5 years. Univariable analysis identified α-fetoprotein more than 1000 ng/ml at relapse, recurrence treatment, extrahepatic location, and time to recurrence more than 2 years as prognostic factors. In multivariable analysis, recurrence treatment, extrahepatic location, and time to recurrence more than 2 years were independent predictors of better survival. Conclusion: In a large Brazilian cohort of LT recipients with HCC, post-LT HCC recurrence occurred in 8% and impacted significantly on the OS. Patients with early recurrence presented a worse prognosis. However, treatment of recurrence improved outcomes, highlighting the importance of early diagnosis.

4 September 2009 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
ACA.L. Chagas
A.L. Chagas
LKL.O.O. Kikuchi
L.O.O. Kikuchi
COC.P.M.S. Oliveira
C.P.M.S. Oliveira
DVD.C.P. Vezozzo
D.C.P. Vezozzo
EME.S. Mello
E.S. Mello
FCF.J. Carrilho
F.J. Carrilho
Non-alcoholic steatohepatitis (NASH) has been associated with hepatocellular carcinoma (HCC) often arising in histologically advanced disease when steatohepatitis is not active (cryptogenic cirrhosis). Our objective was to characterize patients with HCC and active, histologically defined steatohepatitis. Among 394 patients with HCC detected by ultrasound imaging over 8 years and staged by the Barcelona Clinic Liver Cancer (BCLC) criteria, we identified 7 cases (1.7%) with HCC occurring in the setting of active biopsy-proven NASH. All were negative for other liver diseases such as hepatitis C, hepatitis B, autoimmune hepatitis, Wilson disease, and hemochromatosis. The patients (4 males and 3 females, age 63 +/- 13 years) were either overweight (4) or obese (3); 57% were diabetic and 28.5% had dyslipidemia. Cirrhosis was present in 6 of 7 patients, but 1 patient had well-differentiated HCC in the setting of NASH without cirrhosis (fibrosis stage 1) based on repeated liver biopsies, the absence of portal hypertension by clinical and radiographic evaluations and by direct surgical inspection. Among the cirrhotic patients, 71.4% were clinically staged as Child A and 14.2% as Child B. Tumor size ranged from 1.0 to 5.2 cm and 5 of 7 patients were classified as early stage; 46% of all nodules were hyper-echoic and 57% were <3 cm. HCC was well differentiated in 1/6 and moderately differentiated in 5/6. Alpha-fetoprotein was <100 ng/mL in all patients. HCC in patients with active steatohepatitis is often multifocal, may precede clinically advanced disease and occurs without diagnostic levels of alpha-fetoprotein. Importantly, HCC may occur in NASH in the absence of cirrhosis. More aggressive screening of NASH patients may be warranted.

1 March 2015 in Clinics
Verified
Journal Article
Open access
PDF file
ACAline Lopes Chagas
Aline Lopes Chagas
LKLuciana Kikuchi
Luciana Kikuchi
PHPaulo Herman
Paulo Herman
RARegiane S.S.M. Alencar
Regiane S.S.M. Alencar
CTClaudia M. Tani
Claudia M. Tani
VAVenancio A.F. Alves
Venancio A.F. Alves
Key words: Fibrolamellar hepatocellular carcinoma; Liver cancer; Liver neoplasms; Hepatocellular carcinoma (fibrolamellar variant)

1 January 2020 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
ACAline Lopes Chagas
Aline Lopes Chagas
AMAngelo Alves de Mattos
Angelo Alves de Mattos
FCFlair Jose Carrilho
Flair Jose Carrilho
PBPaulo Lisboa Bittencourt
Paulo Lisboa Bittencourt
DVDenise Cerqueira Paranaguá Vezozzo
Denise Cerqueira Paranaguá Vezozzo
TCThaisa de Fátima Almeida Costa
Thaisa de Fátima Almeida Costa
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The Brazilian Society of Hepatology (SBH) published in 2015 its first recommendations about the management of HCC. Since then, new data have emerged in the literature, prompting the governing board of SBH to sponsor a single-topic meeting in August 2018 in São Paulo. All the invited experts were asked to make a systematic review of the literature reviewing the management of HCC in subjects with cirrhosis. After the meeting, all panelists gathered together for the discussion of the topics and the elaboration of updated recommendations. The text was subsequently submitted for suggestions and approval of all members of the Brazilian Society of Hepatology through its homepage. The present manuscript is the final version of the reviewed manuscript containing the recommendations of SBH.

18 December 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
APAna Maria Passos-Castilho
Ana Maria Passos-Castilho
VCValdemir Melechco Carvalho
Valdemir Melechco Carvalho
KCKarina Helena Morais Cardozo
Karina Helena Morais Cardozo
LKLuciana Kikuchi
Luciana Kikuchi
ACAline Lopes Chagas
Aline Lopes Chagas
CGCelso Francisco Hernandes Granato
Celso Francisco Hernandes Granato
Chronic hepatitis B (CHB) virus infection is a major cause of hepatocellular carcinoma (HCC), as late diagnosis is the main factor for the poor survival of patients. There is an urgent need for accurate biomarkers for early diagnosis of HCC. The aim of the study was to explore the serum lipidome profiles of hepatitis B-related HCC to identify potential diagnostic biomarkers. An ultraperformance liquid chromatography mass spectrometry (UPLC-MS) lipidomic method was used to characterize serum profiles from HCC (n = 32), liver cirrhosis (LC) (n = 30), CHB (n = 25), and healthy subjects (n = 34). Patients were diagnosed by clinical laboratory and imaging evidence and all presented with CHB while healthy controls had normal liver function and no infectious diseases. The UPLC-MS-based serum lipidomic profile provided more accurate diagnosis for LC patients than conventional alpha-fetoprotein (AFP) detection. HCC patients were discriminated from LC with 78 % sensitivity and 64 % specificity. In comparison, AFP showed sensitivity and specificity of 38 % and 93 %, respectively. HCC was differentiated from CHB with 100 % sensitivity and specificity using the UPLC-MS approach. Identified lipids comprised glycerophosphocolines, glycerophosphoserines and glycerophosphoinositols. UPLC-MS lipid profiling proved to be an efficient and convenient tool for diagnosis and screening of HCC in a high-risk population.

14 March 2020 in Liver International
Verified
Journal Article
Closed access
PDF file
ÁDÁlvaro Díaz-González
Álvaro Díaz-González
MZMarco Sanduzzi Zamparelli
Marco Sanduzzi Zamparelli
LFLeonardo Da Fonseca
Leonardo Da Fonseca
GCGiovan Giuseppe Di Costanzo
Giovan Giuseppe Di Costanzo
RARogerio Alves
Rogerio Alves
MRMaria Reig
Maria Reig